v3.26.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash flows - operating activities    
Net earnings $ 2,582 $ 2,801
Adjustments to reconcile net earnings to cash provided from operating activities    
Provision for credit losses 3,802 3,783
Deferred income taxes (10) 171
Depreciation and amortization 438 375
All other operating activities 607 358
(Increase) decrease in interest and fees receivable (478) (271)
(Increase) decrease in other assets 150 114
Increase (decrease) in accrued expenses and other liabilities 10 66
Cash provided from (used for) operating activities 7,101 7,397
Cash flows - investing activities    
Maturity and sales of debt securities 1,962 1,571
Purchases of debt securities (3,988) (1,177)
Acquisition of loan receivables (809) 0
Net (increase) decrease in loan receivables, including held for sale (2,753) 183
All other investing activities (610) (789)
Cash provided from (used for) investing activities (6,198) (212)
Borrowings of consolidated securitization entities    
Proceeds from issuance of securitized debt 1,495 1,495
Maturities and repayment of securitized debt (1,000) (1,675)
Senior and subordinated unsecured notes    
Proceeds from issuance of senior and subordinated unsecured notes 1,837 1,788
Maturities and repayment of senior and subordinated unsecured notes (500) (2,650)
Dividends paid on preferred stock (70) (62)
Proceeds from issuance of preferred stock 494 0
Net increase (decrease) in deposits 1,802 (2,182)
Purchases of treasury stock (2,878) (1,979)
Dividends paid on common stock (314) (321)
All other financing activities (89) (67)
Cash provided from (used for) financing activities 777 (5,653)
Increase (decrease) in cash and equivalents, including restricted amounts 1,680 1,532
Cash and equivalents, including restricted amounts, at beginning of period 15,017 14,755
Cash and equivalents 15,901 16,245
Restricted cash and equivalents included in other assets 796 42
Total cash and equivalents, including restricted amounts, at end of period $ 16,697 $ 16,287